• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS

    4/20/23 6:53:00 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LCI alert in real time by email

    Company Expects No Impact on Operations

    Negotiations with Key Secured Creditors Progressing Toward a Balance Sheet Strengthening Transaction

    TREVOSE, Pa., April 20, 2023 /PRNewswire/ -- Lannett Company, Inc. (LCI) ("Lannett" or "the Company") today announced that it received a written notice from the New York Stock Exchange ("NYSE") dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company's common stock from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company has fallen below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization of at least $15,000,000 over a consecutive 30-trading day period.

    Lannett Logo (PRNewsFoto/Lannett Company, Inc.)

    The NYSE suspended trading in the Company's common stock immediately after market close on April 19, 2023. The Company's common stock will begin trading in the over-the-counter market commencing on April 20, 2023. The common stock will retain the ticker symbol (LCI).

    The NYSE will apply to the Securities and Exchange Commission (the "SEC") to delist the common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE's decision. The Company does not expect to appeal the delisting.

    The Company continues to engage in active discussions with key secured creditors regarding a potential deleveraging transaction, as previously announced. While the Company cannot provide any assurance as to if or when it will consummate any such transactions or the terms of any such transactions, the Company expects to be able to reach an agreement with its key secured creditors in the near term on such a transaction. 

    About Lannett Company, Inc.:

    Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. For more information, visit the company's website at www.lannett.com.

    Forward Looking Statements:

    This press release contains forward-looking statements which are not historical facts made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not promises or guarantees and investors are cautioned that all forward-looking statements involve risks and uncertainties, including but not limited to the impact of competitive products and pricing, product demand and market acceptance, new product development, acquisition-related challenges, the regulatory environment, interest rate fluctuations, reliance on key strategic alliances, availability of raw materials, fluctuations in operating results, the impact of the delisting, including under the indenture governing our convertible notes, the impact of failure to pay interest when due on our debt, the ability to implement a recapitalization, restructuring or similar transaction and the terms of such a transaction, the impact if any recapitalization, restructuring or similar transaction is implemented under applicable bankruptcy laws, including Chapter 11 of the U.S. Bankruptcy Code, and other risks detailed from time to time in our filings with the SEC. These statements are based on management's current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements which speak only as of the date made. Lannett is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise and other events or factors, many of which are beyond our control, including those resulting from such events, or the prospect of such events, such as public health issues including health epidemics or pandemics, such as the outbreak of the novel coronavirus, whether occurring in the United States or elsewhere, which could disrupt our operations, disrupt the operations of our suppliers and business development and other strategic partners, disrupt the global financial markets or result in political or economic instability.

    The information in this press release should be read in conjunction with information in the Company's filings with the SEC, including its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

    Contact:       

    C Street Advisory Group



    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nyse-to-suspend-trading-immediately-in-lannett-company-inc-lci-and-commence-delisting-proceedings-301802729.html

    SOURCE Lannett Company, Inc.

    Get the next $LCI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LCI

    DatePrice TargetRatingAnalyst
    8/31/2021$7.00 → $6.00Neutral
    Roth Capital
    More analyst ratings

    $LCI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LEVOFLOXACIN issued to LANNETT CO INC

    Submission status for LANNETT CO INC's drug LEVOFLOXACIN (SUPPL-11) with active ingredient LEVOFLOXACIN has changed to 'Approval' on 09/20/2024. Application Category: ANDA, Application Number: 205222, Application Classification: Labeling

    9/24/24 4:39:48 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for MYCOPHENOLATE MOFETIL issued to LANNETT CO INC

    Submission status for LANNETT CO INC's drug MYCOPHENOLATE MOFETIL (SUPPL-7) with active ingredient MYCOPHENOLATE MOFETIL has changed to 'Approval' on 08/13/2024. Application Category: ANDA, Application Number: 214525, Application Classification: REMS

    8/15/24 4:43:42 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE issued to LANNETT CO INC

    Submission status for LANNETT CO INC's drug SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE (ORIG-1) with active ingredient MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE has changed to 'Approval' on 07/15/2024. Application Category: ANDA, Application Number: 209941, Application Classification:

    7/17/24 4:37:21 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS

    Company Expects No Impact on Operations Negotiations with Key Secured Creditors Progressing Toward a Balance Sheet Strengthening Transaction TREVOSE, Pa., April 20, 2023 /PRNewswire/ -- Lannett Company, Inc. (LCI) ("Lannett" or "the Company") today announced that it received a written notice from the New York Stock Exchange ("NYSE") dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company's common stock from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company has fallen below the NYSE's continued listing standard requiring listed companies to maintain an average glo

    4/20/23 6:53:00 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LANNETT SHARES UPDATE

    Announces Positive Results from Pivotal Clinical Insulin Trial that Demonstrates Biosimilarity to Reference Product Productive Conversations with Key Secured Creditors Toward a Balance Sheet Strengthening, Recapitalization or Restructuring Transaction Ongoing As Company Enters Grace Period for Failure to Pay Interest on Convertible Notes TREVOSE, Pa., April 4, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) (the "Company") today shared a business update as it focuses on strategically positioning the Company to continue manufacturing and delivering safe, affordable, effective, life-enhancing generic pharmaceutical products for its valued patients and customers.

    4/4/23 6:55:00 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE

    Q2 Business and Financial Highlights: Net Sales were $80.9 MillionGross Margin was 18%, Adjusted Gross Margin was 19%Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters$19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31stPipeline Updates: Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current YearExecuted Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin

    2/1/23 4:15:00 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    SEC Filings

    View All

    SEC Form EFFECT filed by Lannett Co Inc

    EFFECT - LANNETT CO INC (0000057725) (Filer)

    6/26/23 12:15:08 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Lannett Co Inc

    EFFECT - LANNETT CO INC (0000057725) (Filer)

    6/26/23 12:15:20 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Lannett Co Inc

    EFFECT - LANNETT CO INC (0000057725) (Filer)

    6/26/23 12:15:14 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Chapman John C bought $10,200 worth of shares (20,000 units at $0.51), increasing direct ownership by 13% to 174,324 units

    4 - LANNETT CO INC (0000057725) (Issuer)

    11/18/22 4:09:03 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Lepore Patrick G bought $49,000 worth of shares (100,000 units at $0.49), increasing direct ownership by 21% to 587,145 units

    4 - LANNETT CO INC (0000057725) (Issuer)

    11/14/22 4:16:01 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Crew Timothy C bought $7,200 worth of shares (15,000 units at $0.48), increasing direct ownership by 3% to 604,291 units

    4 - LANNETT CO INC (0000057725) (Issuer)

    11/14/22 4:14:53 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital reiterated coverage on Lannett with a new price target

    Roth Capital reiterated coverage of Lannett with a rating of Neutral and set a new price target of $6.00 from $7.00 previously

    8/31/21 8:50:46 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital reiterated coverage on Lannett with a new price target

    Roth Capital reiterated coverage of Lannett with a rating of Neutral and set a new price target of $7.00 from $7.50 previously

    6/10/21 9:57:43 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Lannett Co Inc (Amendment)

    SC 13G/A - LANNETT CO INC (0000057725) (Subject)

    2/10/23 9:46:33 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lannett Co Inc (Amendment)

    SC 13G/A - LANNETT CO INC (0000057725) (Subject)

    6/3/22 1:48:32 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Lannett Co Inc (Amendment)

    SC 13G/A - LANNETT CO INC (0000057725) (Subject)

    2/11/22 8:19:58 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LCI
    Financials

    Live finance-specific insights

    View All

    NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT COMPANY, INC. (LCI) AND COMMENCE DELISTING PROCEEDINGS

    Company Expects No Impact on Operations Negotiations with Key Secured Creditors Progressing Toward a Balance Sheet Strengthening Transaction TREVOSE, Pa., April 20, 2023 /PRNewswire/ -- Lannett Company, Inc. (LCI) ("Lannett" or "the Company") today announced that it received a written notice from the New York Stock Exchange ("NYSE") dated April 19, 2023, notifying the Company that the NYSE will commence proceedings to delist the Company's common stock from the NYSE. The NYSE reached this determination pursuant to Section 802.01B of the NYSE's Listed Company Manual because the Company has fallen below the NYSE's continued listing standard requiring listed companies to maintain an average glo

    4/20/23 6:53:00 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE

    Q2 Business and Financial Highlights: Net Sales were $80.9 MillionGross Margin was 18%, Adjusted Gross Margin was 19%Net Sales, Gross Margin and Adjusted Gross Margin Up Versus Preceding Two Quarters$19 Million Income Tax Refund Received, Cash Balance of $56 Million at December 31stPipeline Updates: Pivotal Biosimilar Insulin Glargine Clinical Trial Top-line Results Anticipated in Current Quarter; BLA Filing Targeted for Middle of Calendar 2023Positive Results from Study of Biosimilar Insulin Aspart vs US NovoLog®; Commencement of Pivotal Trial Anticipated by Fall of Current YearExecuted Sub-License Agreement Related to Insulin Pen Delivery Device, Improving Ability to Freely Market Insulin

    2/1/23 4:15:00 PM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1

    TREVOSE, Pa., Jan. 25, 2023 /PRNewswire/ -- Lannett Company, Inc. (NYSE:LCI) today announced that it will report financial results for its fiscal 2023 second quarter on Wednesday, February 1, 2023, after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company's performance. The conference call will be available to interested parties by dialing 877-407-9716 from the U.S. or Canada, or 201-493-6779 from international locations. The call will be broadcast via the Internet at www.Lannett.com. Listeners a

    1/25/23 6:52:00 AM ET
    $LCI
    Biotechnology: Pharmaceutical Preparations
    Health Care